Mesoblast (NASDAQ:MESO), a global leader in allogeneic cellular medicines, has reported net sales of $30.3 million for its flagship product, Ryoncil (remestemcel-L-rknd), for the third fiscal quarter ended March 31, 2026.
The quarterly performance was driven by robust demand in February and March, which effectively offset typical pharmaceutical seasonality observed in January.
Following its commercial rollout in April 2025, Ryoncil's total revenue for its first year on the market is now approaching the $100 million milestone.
Ryoncil holds the distinction of being the first mesenchymal stromal cell (MSC) product approved by the FDA and remains the only approved therapy for children under 12 with steroid-refractory acute graft-versus-host disease (SR-aGvHD).
The steady commercial uptake has significantly strengthened Mesoblast's balance sheet, providing the capital necessary to advance its broader pipeline of regenerative medicines.
The company is currently preparing for its inaugural R&D Day on April 8, 2026, in New York City.
During the event, leadership and key opinion leaders are expected to outline the long-term growth strategy for the Ryoncil franchise, including its application in biologic-resistant inflammatory bowel disease.
Additionally, the company will provide updates on rexlemestrocel-L, its candidate for cardiovascular and orthopedic indications.
Financially, Mesoblast has previously indicated that it anticipates full-year fiscal 2026 Ryoncil net revenue to range between $110 million and $120 million.